Last reviewed · How we verify
Normoxic Allogenic UCMSC — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Normoxic Allogenic UCMSC (Normoxic Allogenic UCMSC) — Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Normoxic Allogenic UCMSC TARGET | Normoxic Allogenic UCMSC | Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Normoxic Allogenic UCMSC CI watch — RSS
- Normoxic Allogenic UCMSC CI watch — Atom
- Normoxic Allogenic UCMSC CI watch — JSON
- Normoxic Allogenic UCMSC alone — RSS
Cite this brief
Drug Landscape (2026). Normoxic Allogenic UCMSC — Competitive Intelligence Brief. https://druglandscape.com/ci/normoxic-allogenic-ucmsc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab